Janssen files darunavir/cobicistat for HIV with the FDA
Janssen R&D has submitted a New Drug Application to the FDA seeking approval for a once-daily fixed-dose antiretroviral combination tablet containing (Prezista) darunavir with cobicistat, developed by Gilead Sciences, use in combination with other Human Immunodeficiency Virus (HIV-1) medicines.
If approved, the fixed-dose combination tablet will be marketed under a new brand name and will, for the first time, offer an additional therapeutic option that eliminates the need to take a boosting agent in a separate tablet with once-daily darunavir. The combination was filed with the EU in October 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins